



Menopause and diabetes: EMAS clinical guide



Radoslaw Slopian^{a,1}, Ewa Wender-Ozegowska^{b,1}, Anita Rogowicz-Frontczak^c,
 Blazej Meczekalski^a, Dorota Zozulinska-Ziolkiewicz^d, Jesse D. Jaremek^d, Antonio Cano^e,
 Peter Chedraui^f, Dimitrios G. Goulis^g, Patrice Lopes^{h,i}, Gita Mishra^j, Alfred Mueck^k,
 Margaret Rees^l, Levent M. Senturk^m, Tommaso Simonciniⁿ, John C. Stevenson^o, Petra Stute^p,
 Pauliina Tuomikoski^q, Stavroula A. Paschou^r, Panagiotis Anagnostis^g, Irene Lambrinoudaki^{r,*}

^a Department of Gynecological Endocrinology, Poznań University of Medical Sciences, Poznan, Poland

^b Department of Reproduction, Poznań University of Medical Sciences, Poznan, Poland

^c Department of Diabetology, Poznań University of Medical Sciences, Poznan, Poland

^d Poznań University of Medical Sciences, Poznan, Poland

^e Department of Pediatrics, Obstetrics and Gynecology, University of Valencia and INCLIVA, Valencia, Spain

^f Instituto de Investigación e Innovación de Salud Integral (ISAIN), Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador

^g Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Greece

^h Nantes, France Polyclinique de l'Atlantique Saint Herblain, F 44819 St Herblain, France

ⁱ Université de Nantes, F 44093 Nantes Cedex, France

^j School of Public Health, Faculty of Medicine, University of Queensland, Brisbane 4006, Australia

^k University Women's Hospital of Tuebingen, Calwer Street 7, 72076 Tuebingen, Germany

^l Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK

^m Istanbul University Cerrahpasa School of Medicine, Dept. of Obstetrics and Gynecology, Division of Reproductive Endocrinology, IVF Unit, Istanbul, Turkey

ⁿ Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100, Pisa, Italy

^o National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London SW3 6NP, UK

^p Department of Obstetrics and Gynecology, University Women's Hospital, Bern, Switzerland

^q Helsinki University and Helsinki University Hospital, Eira Hospital, Helsinki, Finland

^r Second Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Greece

ARTICLE INFO

Keywords:

Type 2 diabetes mellitus

Menopause

Menopausal hormone therapy

ABSTRACT

Introduction: Whether menopause increases the risk of type 2 diabetes mellitus (T2DM) independently of ageing has been a matter of debate. Controversy also exists about the benefits and risks of menopausal hormone therapy (MHT) in women with T2DM.

Aims: To summarise the evidence on 1) the effect of menopause on metabolic parameters and the risk of T2DM, 2) the effect of T2DM on age at menopause, 3) the effect of MHT on the risk of T2DM, and 4) the management of postmenopausal women with T2DM.

Materials and methods: Literature review and consensus of experts' opinions.

Results and conclusion: Metabolic changes during the menopausal transition include an increase in and the central redistribution of adipose tissue, as well as a decrease in energy expenditure. In addition, there is impairment of insulin secretion and insulin sensitivity and an increase in the risk of T2DM. MHT has a favourable effect on glucose metabolism, both in women with and in women without T2DM, while it may delay the onset of T2DM. MHT in women with T2DM should be administered according to their risk of cardiovascular disease (CVD). In women with T2DM and low CVD risk, oral oestrogens may be preferred, while transdermal 17β-oestradiol is preferred for women with T2DM and coexistent CVD risk factors, such as obesity. In any case, a progestogen with neutral effects on glucose metabolism should be used, such as progesterone, dydrogesterone or transdermal norethisterone. Postmenopausal women with T2DM should be managed primarily with lifestyle intervention, including diet and exercise. Most of them will eventually require pharmacological therapy. The

* Corresponding author at: Second Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Greece 4, Dorylaiou Street, Athens, GR 11521, Greece.

E-mail address: ilambrinoudaki@med.uoa.gr (I. Lambrinoudaki).

¹ These two authors contributed equally to the paper.

selection of antidiabetic medications should be based on the patient's specific characteristics and comorbidities, as well on the metabolic, cardiovascular and bone effects of the medications.

1. Introduction

Diabetes mellitus (DM) is a public health problem, especially in developed countries. It affects about 9.1% of the adult population in Europe and 13.3% in the United States of America [1]. The greater prevalence of DM in developed countries is broadly associated with ageing of the population [2]. Between 2015 and 2030, the world population aged over 60 years is projected to increase by 56%, from 901 million to 1.4 billion; by 2050 it is expected to reach nearly 2.1 billion [3]. These data suggest that the number of postmenopausal women with DM will grow substantially. The management of menopause in women with type 2 diabetes mellitus (T2DM) is challenging, as the precise nature of the risks and benefits of menopausal hormone therapy (MHT) in women with T2DM are still unclear.

The aim of this clinical guide is to summarise the evidence on 1) the effect of menopause on metabolic parameters and the risk of T2DM, 2) the effect of T2DM on age at menopause, 3) the effect of MHT on the risk of T2DM, and 4) the management of postmenopausal women with T2DM.

2. Metabolic changes during the menopausal transition

Menopause is the permanent cessation of menses due to oocyte depletion. The result is an abrupt decrease in endogenous oestradiol (E_2). During the transition to menopause, women undergo phenotypical, metabolic and biochemical changes which increase the risk of T2DM. Whether these changes are independent of ageing itself has been a matter of debate [4].

Women gain weight during the menopausal transition. While this may be influenced by age rather than menopause *per se* [5], the menopausal transition is independently associated with an increase in fat mass, especially in the abdominal region [6,7]. Perimenopausal women, furthermore, undergo a decrease in lean body mass and a significant reduction in energy expenditure, mainly from fat oxidation, which favour an increase in total body and visceral fat, without major changes in energy intake [6,7]. Visceral adiposity augments the production of proinflammatory cytokines, increases circulating free fatty acids and promotes the generation of reactive oxygen species, contributing to the development of insulin resistance [8]. On the other hand, menopause is a state of relative androgen excess: the postmenopausal ovary continues to secrete androgens, with higher bioavailability, due to the decrease in sex hormone-binding globulin (SHBG) seen during the transition. These hormonal changes further increase insulin resistance [9]. The prevalence of the metabolic syndrome, therefore, increases steeply after menopause, to between 30% and 70%, compared with 14–45% in women of reproductive age [8,10]. The metabolic syndrome has its pathogenetic origin in insulin resistance and is characterised by abnormal glucose metabolism, hypertension, central obesity and dyslipidaemia [11–14].

Beyond the metabolic changes triggered by menopause, experimental studies suggest that decreased E_2 concentrations, as well as decreased oestrogen receptor- α ($ER\alpha$) activity, can cause insulin resistance in peripheral tissues [15,16]. Pancreatic β -cells have to compensate for insulin resistance to maintain glucose homeostasis; only when β -cell dysfunction coexists with insulin resistance does T2DM ultimately develop. Animal studies suggest an adverse effect of hypogonadism on insulin secretion. Ovariectomised rodents consistently present impaired β -cell function, while decreased E_2 action via $ER\alpha$ and $ER\beta$ seem to affect the survival of β -cells and the secretion of insulin, respectively [17–19].

3. Effect of menopause on the incidence of T2DM

Given the adverse metabolic changes associated with the menopausal transition, menopause is associated with an increased risk of T2DM. The Study of Women's Health Across the Nation (SWAN) suggested that lower E_2 concentrations resulted in a 47% higher risk of T2DM during the menopausal transition [20]. This finding was different from the initial results, which had suggested that the glucose dysregulation observed during menopause was associated with age and not with the decline of ovarian function [21,22]. Furthermore, the European Prospective Investigation into Cancer (EPIC)-InterAct, after following women for 11 years, showed that menopause before the age of 40 years was associated with a 32% greater risk of T2DM [23]. Another observational study, from China, provided evidence that menopause before the age of 45 years was associated with a 20% greater risk of T2DM compared with the average age of menopause [24]. In accordance with these findings, studies in women after ovariectomy have reported that their risk of T2DM is up to 57% higher than for women who have not undergone ovariectomy [25,26]. A recent analysis of data from the Women's Health Initiative (WHI) study, examining 124,379 postmenopausal women, concluded that women with a reproductive lifetime (difference between age at menarche and age at last period) of less than 30 years had a 37% higher risk of T2DM than women with a reproductive lifetime of 36–40 years. These results were reached after adjustment for chronological age [27]. Data from the same population showed that the report of any climacteric symptom was associated with an 18% increase in the incidence of T2DM (hazard ratio (HR) 1.18, 95% confidence interval (CI) 1.14–1.22). The risk increased in parallel with the severity and duration of symptoms, independent of obesity [28].

4. Effect of DM on age at menopause

Several studies have indicated an earlier age at menopause in women with type 1 diabetes mellitus (T1DM) than for women without T1DM. The prevalence of premature ovarian insufficiency in patients with T1DM is also higher, which might be related to the fact that both conditions are associated with autoimmunity [29,30]. The Familial Autoimmune and Diabetes study showed that women with T1DM experienced menopause at an earlier age (41.6 years) than their sisters (at age 49.9) or unrelated controls without diabetes (at age 48 years) [29]. Similarly, the European Prospective Investigation into Cancer and Nutrition (a cohort study) found that onset of diabetes before the age of 20 was associated with menopause at a younger age [30].

In contrast, other studies do not support an effect of diabetes on age at menopause. In the Ovarian Ageing in type 1 Diabetes mellitus (OVADIA) study, age at menopause was similar for women with and without the disease (49.8 years) [31]. Similarly, the results of the Epidemiology of Diabetes Interventions and Complications (EDIC) study, which is a follow-up of the Diabetes Control and Complication Trial (DCCT), reported that age at menopause was not related to the therapy regimen or glycaemic control [32]. In a large population-based Finnish study of women with childhood-onset diabetes, the median age at menopause in the patient group was similar to that in the general population. Only the presence of advanced microvascular complications, such as renal disease and proliferative retinopathy, was associated with earlier menopause [33].

Furthermore, T2DM may accelerate the onset of menopause [30]. A study of 6079 middle-aged women from 11 Latin American countries showed that the proportion of middle-aged women with T2DM who had been through the menopause was three times that in the women without T2DM [34]. Moreover, women with a later onset of T2DM

(over 50 years) tended to have a later age of menopause, but this could have been associated with their higher body mass index (BMI) [34].

5. Impact of MHT on the risk of T2DM

MHT has a beneficial effect on various metabolic parameters, including a decrease in abdominal fat deposition, an increase in lipid oxidation and enhancement of energy expenditure [35,36]. Evidence also suggests that oestrogens improve insulin sensitivity through a direct effect on ERs in liver, muscle and adipose tissue [37,38]. Studies in rodents have shown that oestrogens may augment insulin secretion in pancreatic β -cells too [17].

A large body of evidence indicates that MHT reduces the risk of T2DM. The incidence of T2DM in the MHT arm was reduced by 35% in the Heart and Estrogen/progestin Replacement Study (HERS) [39], and by 21% in the Women's Health Initiative (WHI) study [40]. The same effect was reported in two prospective observational studies, the Nurses' Health Study (NHS), where the use of MHT resulted in a 20% reduction in the incidence of T2DM [41], and the Etude Epidémiologique de Femmes de la Mutuelle Générale de l'Éducation Nationale (E3N), where the incidence of T2DM was 25% lower in women on MHT [42]. A meta-analysis of 107 trials showed that MHT reduced insulin resistance by 13% and new-onset T2DM by 30% [43].

Most large trials have assessed women on treatment with conjugated equine oestrogens (CEE) combined with medroxyprogesterone acetate (MPA); there are limited data regarding other types of MHT. Among the E3N cohort of 63,624 postmenopausal women, 1220 new-onset T2DM cases were identified, and the use of oral MHT was associated with a lower risk of new-onset T2DM than the use of transdermal MHT [42]. Because of the first-pass metabolism in the liver, oral CEE has stronger beneficial effects on insulin resistance, suppression of hepatic glucose production and cholesterol concentrations [43,44]. However, CEE increases the hepatic synthesis of triglycerides, C-reactive protein (CRP) and coagulation factors, and may increase the risk of thrombosis [45]. Furthermore, progestogens have been associated with the development of insulin resistance; in most trials, the beneficial effects of oestrogens were decreased by the addition of a progestogen, in a dose-dependent manner. Progesterone, norethisterone acetate (NETA) and dydrogesterone are likely to be more neutral than MPA and levonorgestrel, which are more androgenic [46–51].

6. MHT in women with T2DM

In women with T2DM, MHT improves glycaemia, insulin resistance and other components of the metabolic syndrome [43]. Despite this, the frequency of MHT use among women with T2DM is about 50% lower than in the general population. This is probably because T2DM was broadly considered in the past to be a CVD equivalent [52], and this rationale still deters many clinicians from prescribing MHT to patients with T2DM. However, given the beneficial effects of MHT on glycaemic control, an individualised approach in treating menopausal symptoms should be considered. Women with T2DM may be excellent candidates for MHT, after careful evaluation of their CVD risk [35,53–55]. In peri- or recently postmenopausal women with T2DM and low CVD risk, oral oestrogens may be preferred. In obese women with T2DM or in any woman at moderate risk of CVD, transdermal 17β -oestradiol is the preferred treatment. In any case, a progestogen with minimal effects on glucose metabolism should be used, like progesterone, dydrogesterone or transdermal norethisterone [35,53–56].

7. Management of T2DM in women during and after menopause

Many of the adverse metabolic consequences of the menopause can be countered by lifestyle changes, such as optimal diet, increase in physical activity, cessation of smoking and decrease in alcohol consumption. Lifestyle intervention should be the cornerstone of

management in women with T2DM entering the menopause. Weight loss is very important, not only for the treatment of T2DM but also for its prevention [57]. However, as bone health and sarcopenia are important concerns during the postmenopausal period, only gradual and modest weight loss (5–7% of initial body weight annually) should be recommended [58,59]. Specific clinical nutritional recommendations include consumption of mono- and polyunsaturated fat rather than saturated forms, reduction in the total amount of carbohydrates and a preference for those deriving from fruits and whole grains, as well as protein intake being mainly from fish, poultry or skimmed dairy products. Nutrition programmes that provide 1200–1500 kcal/day or that create an energy deficit of 500–750 kcal/day can result in the desired weight loss. Consumption of nuts and seeds, appropriate intake of calcium and vitamin D, and low intakes of alcohol and sodium are additional crucial dietary changes. The recommended calcium and vitamin D daily intakes for women older than 50 years with a risk of fracture are 1000–1200 mg and 600–800 IU, respectively [58–62].

Physical exercise prevents weight gain and muscle atrophy, and improves bone quality and glycaemic control. Women with T2DM should be encouraged to engage in regular aerobic physical activity – at least 150 min per week of moderate exercise or at least 75 min of vigorous exercise per week. Anaerobic activities targeting major muscle groups should also be performed. Physical activity increases muscle mass and because muscle is denser than fat it may limit weight loss despite fat reduction. In that case, women should be informed that this is still excellent for their health and the indicator to be checked should then be waist circumference [57,60].

Smoking represents an important risk factor for many diseases associated with menopause and ageing, such as CVD, osteoporosis and cancer. Therefore, smoking discontinuation should be an essential part of routine clinical consultation [60].

Most postmenopausal women with T2DM will eventually require pharmacological therapy. Metformin, sulfonylureas, thiazolidinediones (TZDs), dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-dependent glucose transporter-2 inhibitors (SGLT-2i) and insulin are the most commonly used medications. They have different metabolic, cardiovascular and bone effects [63–65], and the most suitable agent for any particular woman should be selected according to these different effects after taking into consideration the woman's specific characteristics and comorbidities. Metformin should be used as the first-line treatment, while DPP-4i and GLP-1RA may be useful second-line options because of their beneficial (or at least neutral) effects on bones. TZDs should be avoided in women with osteoporosis and increased fracture risk, as should canagliflozin, an SGLT-2i; other SGLT-2i are not well-validated options [58,63–65].

8. Conclusions

Menopause is associated with an adverse metabolic profile and possibly an increase in T2DM risk. MHT has a favourable effect on glucose homeostasis both in women with and in women without T2DM. Women with T2DM can receive MHT after careful assessment of their CVD risk. They should also be managed with lifestyle interventions, including diet, exercise, smoking cessation and decrease in alcohol consumption, with a combined focus on metabolic, cardiovascular and bone health. The most suitable antidiabetic agents should be selected according to the individual's cardiometabolic and fracture risk.

Contributors

R. Słopień, A. Rogowicz-Frontczak, B. Męczałski, D. Zozulińska-Ziółkiewicz, J.D. Jarek and E. Wender-Ożegowska prepared the initial draft, which was revised by Irene Lambrinouaki, Panayotis Anagnostis and Stavroula A. Paschou. The revised paper was circulated to all other named authors (EMAS board members) for comments and approval; production was coordinated by Irene Lambrinouaki and Margaret Rees.

Conflict of interest

- 1 Radoslaw Slopian, none declared.
- 2 Ewa Wender-Ozegowska, none declared.
- 3 Anita Rogowicz-Frontczak, none declared.
- 4 Blazej Meczekalski, none declared.
- 5 Dorota Zozulinska-Ziolkiewicz, none declared.
- 6 Jesse D. Jaremek, none declared.
- 7 Antonio Cano, none declared.
- 8 Peter Chedraui, none declared.
- 9 Dimitrios G. Goulis, none declared.
- 10 Patrice Lopes, none declared.
- 11 Gita Mishra, none declared.
- 12 Alfred Mueck, in the past 5 years, has received research funding by various pharmaceutical companies who produce and/or sell products used as hormone therapy in peri- and postmenopausal women; as well as lecture fees from various pharmaceutical companies for lectures on hormone therapy or other issues of menopause.
- 13 Margaret Rees has received consulting fees in the past 5 years from Metagenics.
- 14 Levent M. Senturk, none declared.
- 15 Tommaso Simoncini, in the past 5 years has received consulting fees from Abbott, Actavis, Bayer and Estetra, as well as research support from Gedeon Richter.
- 16 John C. Stevenson, in the 5 past years has received grants/research support from Abbott, Mylan and Pfizer, consulting fees from Abbott and Pfizer, and speakers' honoraria from Amgen, Bayer, Gedeon Richter, Menarini, Mylan and Theramex.
- 17 Petra Stute, in the past 5 years, has received grants/research support from Medinova AG and Dr Kade/Besins Pharma GmbH, and consulting fees from Max Zeller Söhne AG, Madaus.
- 18 Pauliina Tuomikoski, in the past 5 years has received consulting fees and/or speakers' honoraria from Abbott, Farmasian oppimiskeskus, Gedeon Richter, Mylan and Novo Nordisk, funding for congress trips from Mylan, and research grants from the Finnish Medical Association, 1,3 milj. klubi-klubben, the Päivikki and Sakari Sohlberg Foundation, and a special governmental grant for health sciences research.
- 19 Stavroula A. Paschou, none declared.
- 20 Panayotis Anagnostis, none declared.
- 21 Irene Lambrinoudaki, none declared.

Funding

No funding was received for the preparation of this clinical guide.

Provenance and peer review

This article is an EMAS clinical guide and was not externally peer reviewed.

References

- [1] International Diabetes Federation Diabetes Atlas, (2017) (Accessed 14 June 2018), <http://www.diabetesatlas.org>.
- [2] A. Menke, S. Casagrande, L. Geiss, C.C. Cowie, Prevalence of and trends in diabetes among adults in the United States, 1988–2012, *JAMA* 314 (2015) 1021–1029.
- [3] World Population Aging United Nations New York, (2015) (Accessed 14 June 2018), <http://www.un.org>.
- [4] M.C. Carr, The emergence of the metabolic syndrome with menopause, *J. Clin. Endocrinol. Metab.* 88 (2003) 2404–2411.
- [5] Z.A. Al-Safi, A.J. Polotsky, Obesity and menopause, *Best Pract. Res. Clin. Obstet. Gynaecol.* 29 (2015) 548–553.
- [6] B. Leeners, N. Geary, P.N. Tobler, L. Asarian, Ovarian hormones and obesity, *Hum. Reprod. Update* 23 (2017) 300–321.
- [7] J.C. Lovejoy, C.M. Champagne, L. de Jonge, H. Xie, S.R. Smith, Increased visceral fat and decreased energy expenditure during the menopausal transition, *Int. J. Obes.* 32 (2008) 949–958.
- [8] A. Stefanska, K. Bergmann, G. Sypniewska, Metabolic syndrome and menopause: pathophysiology, clinical and diagnostic significance, *Adv. Clin. Chem.* 72 (2015) 1–75.
- [9] S.A. Paschou, P. Anagnostis, D.G. Goulis, I. Lambrinoudaki, Androgen excess and post-reproductive health, *Maturitas* 115 (2018) 115–116, <https://doi.org/10.1016/j.maturitas.2018.04.005>.
- [10] I. Janssen, L.H. Powell, S. Crawford, B. Lasley, K. Sutton-Tyrrell, Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation, *Arch. Intern. Med.* 168 (2008) 1568–1575.
- [11] V. Wietlisbach, P. Marques-Vidal, K. Kuulasmaa, J. Karvanen, F. Paccaud, The relation of body mass index and abdominal adiposity with dyslipidemia in 27 general populations of the WHO MONICA Project, *Nutr. Metab. Cardiovasc. Dis.* 23 (2013) 432–442.
- [12] U. Gaspard, Hyperinsulinaemia, a key factor of the metabolic syndrome in post-menopausal women, *Maturitas* 62 (2009) 362–365.
- [13] A.C. de Kat, V. Dam, N.C. Onland-Moret, M.J. Eijkemans, F.J. Broekmans, Y.T. van der Schouw, Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study, *BMC Med.* 15 (2017) 2.
- [14] Y. Zhou, X. Zhou, X. Guo, et al., Prevalence and risk factors of hypertension among pre- and post-menopausal women: a cross-sectional study in a rural area of north-east China, *Maturitas* 80 (2015) 282–287.
- [15] E. Riant, A. Wage, H. Cogo, J.F. Arnal, R. Burcelin, P. Gourdy, Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice, *Endocrinology* 150 (2009) 2109–2117.
- [16] G. Bryzgalova, H. Gao, B. Ahren, et al., Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver, *Diabetologia* 49 (2006) 588–597.
- [17] J.P. Tian, F. Mauvais-Jarvis, Importance of oestrogen receptors to preserve functional beta-cell mass in diabetes, *Nat. Rev. Endocrinol.* 8 (2012) 342–351.
- [18] S.E. Kahn, S. Andrikopoulos, C.B. Verchere, F. Wang, R.L. Hull, J. Vidal, Oophorectomy promotes islet amyloid formation in a transgenic mouse model of Type II diabetes, *Diabetologia* 43 (2000) 1309–1312.
- [19] C. Le May, K. Chu, M. Hu, et al., Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice, *Proc. Natl. Acad. Sci. U. S. A.* 103 (2006) 9232–9237.
- [20] S.K. Park, S.D. Harlow, H. Zheng, et al., Association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes, *Diabet. Med.* 34 (2017) 531–538.
- [21] K.A. Matthews, S.L. Crawford, C.U. Chae, et al., Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? *J. Am. Coll. Cardiol.* 54 (2009) 2366–2373.
- [22] K.A. Matthews, C.J. Gibson, S.R. El Khoudary, R.C. Thurston, Changes in cardiovascular risk factors by hysterectomy status with and without oophorectomy: Study of Women's Health Across the Nation, *J. Am. Coll. Cardiol.* 62 (2013) 191–200.
- [23] J.S. Brand, Y.T. van der Schouw, N.C. Onland-Moret, et al., Age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study, *Diabetes Care* 36 (2013) 1012–1019.
- [24] L. Shen, L. Song, H. Li, et al., Association between earlier age at natural menopause and risk of diabetes in middle-aged and older Chinese women: the Dongfeng-Tongji cohort study, *Diabetes Metab.* 43 (2017) 345–350.
- [25] J.M. Malacara, R. Huerta, B. Rivera, S. Esparza, M.E. Fajardo, Menopause in normal and uncomplicated NIDDM women: physical and emotional symptoms and hormone profile, *Maturitas* 28 (1997) 35–45.
- [26] D. Appiah, S.J. Winters, C.A. Hornung, Bilateral oophorectomy and the risk of incident diabetes in postmenopausal women, *Diabetes Care* 37 (2014) 725–733.
- [27] E.S. LeBlanc, K. Kappahn, H. Hedlin, et al., Reproductive history and risk of type 2 diabetes mellitus in postmenopausal women: findings from the Women's Health Initiative, *Menopause* 24 (2017) 64–72.
- [28] K.E. Gray, J.G. Katon, E.S. LeBlanc, et al., Vasomotor symptom characteristics: are they risk factors for incident diabetes? *Menopause* 25 (5) (2018) 520–530.
- [29] J.S. Dorman, A.R. Steenkiste, T.P. Foley, et al., Menopause in type 1 diabetic women: is it premature? *Diabetes* 50 (2001) 1857–1862.
- [30] J.S. Brand, N.C. Onland-Moret, M.J. Eijkemans, et al., Diabetes and onset of natural menopause: results from the European Prospective Investigation into Cancer and Nutrition, *Hum. Reprod.* 30 (2015) 1491–1498.
- [31] F. Yarde, Y.T. van der Schouw, H.W. de Valk, et al., Age at menopause in women with type 1 diabetes mellitus: the OVADIA study, *Hum. Reprod.* 30 (2015) 441–446.
- [32] C. Kim, P.A. Cleary, C.C. Cowie, et al., Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort, *Diabetes Care* 37 (2014) 701–708.
- [33] L. Sjöberg, J. Pitkanen, V. Harjutsalo, L. Haapala, A. Tiitinen, J. Tuomilehto, R. Kaaja, Menopause in women with type 1 diabetes, *Menopause (New York, NY)* 18 (2011) 158–163.
- [34] A. Monterrosa-Castro, J.E. Blumel, K. Portela-Buelvas, et al., Type II diabetes mellitus and menopause: a multinational study, *Climacteric* 16 (2013) 663–672.
- [35] R.J. Santen, D.C. Allred, S.P. Ardoin, et al., Postmenopausal hormone therapy: an Endocrine Society scientific statement, *J. Clin. Endocrinol. Metab.* 95 (2010) s1–s66.
- [36] M. Aubertin-Leheudre, E.D. Goulet, L.J. Dionne, Enhanced rate of resting energy expenditure in women using hormone-replacement therapy: preliminary results, *J. Aging Phys. Act.* 16 (2008) 53–60.
- [37] A.C. Duncan, H. Lyall, R.N. Roberts, et al., The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women, *J. Clin. Endocrinol. Metab.* 84 (1999) 2402–2407.
- [38] I. Mattiasson, M. Rendell, C. Tornquist, S. Jeppsson, U.L. Hulthen, Effects of

- estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women, *Horm. Metab. Res.* 34 (2002) 583–588.
- [39] A.M. Kanaya, D. Herrington, E. Vittinghoff, et al., Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo controlled trial, *Ann. Intern. Med.* 138 (2003) 1–9.
- [40] K.L. Margolis, D.E. Bonds, R.J. Rodabough, et al., Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial, *Diabetologia* 47 (2004) 1175–1187.
- [41] J.E. Manson, E.B. Rimm, G.A. Colditz, et al., A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus, *Ann. Epidemiol.* 2 (1992) 665–673.
- [42] B. de Lauzon-Guillain, A. Fournier, A. Fabre, et al., Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Generale de l'Education Nationale (E3N) cohort, *Diabetologia* 52 (2009) 2092–2100.
- [43] S.R. Salpeter, J.M. Walsh, T.M. Ormiston, E. Greyber, N.S. Buckley, E.E. Salpeter, Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women, *Diabetes Obes. Metab.* 8 (2006) 538–554.
- [44] B.W. Walsh, I. Schiff, B. Rosner, L. Greenberg, V. Ravnkar, F.M. Sacks, Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins, *N. Engl. J. Med.* 325 (1991) 1196–1204.
- [45] M. Canonico, E. Oger, G. Plu-Bureau, J. Conard, G. Meyer, H. Lévesque, N. Trillot, M.T. Barrellier, D. Wahl, J. Emmerich, P.Y. Scarabin, Estrogen and Thromboembolism Risk (ESTHER) Study Group, Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study, *Circulation* 115 (2007) 840–845.
- [46] D.A. Araújo, M.L. Farias, A.T. Andrade, Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus, *Climacteric* 5 (2002) 286–292.
- [47] I.F. Godsland, K. Gangar, C. Walton, et al., Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy, *Metabolism* 42 (1993) 846–853.
- [48] R. Kimmerle, L. Heinemann, T. Heise, et al., Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women, *Menopause* 6 (1999) 36–42.
- [49] C.P. Spencer, I.F. Godsland, A.J. Cooper, D. Ross, M.I. Whitehead, J.C. Stevenson, Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women, *Metabolism* 49 (2000) 742–747.
- [50] K. De Cleyn, P. Buytaert, M. Coppens, Carbohydrate metabolism during hormonal substitution therapy, *Maturitas* 11 (1989) 235–242.
- [51] D. Crook, I.F. Godsland, J. Hull, J.C. Stevenson, Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up, *Br. J. Obstet. Gynaecol.* 104 (1997) 298–304.
- [52] L. Mosca, E.J. Benjamin, K. Berra, et al., Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association, *Circulation* 123 (2011) 1243–1262.
- [53] F. Mauvais-Jarvis, J.E. Manson, J.C. Stevenson, V.A. Fonseca, Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications, *Endocr. Rev.* 38 (2017) 173–188.
- [54] EMAS Care On-Line Section 7: Hormone Therapy in Women with Coexisting Medical Conditions. <http://www.emas-online.org/guidelines/88/57/emas-care-online.html>. (Accessed 13 June 2018).
- [55] I. Lambrinoudaki, M. Brincat, C.T. Erel, et al., EMAS position statement: managing obese postmenopausal women, *Maturitas* 66 (2010) 323–326.
- [56] C.A. Stuenkel, S.R. Davis, A. Gompel, et al., Treatment of symptoms of the menopause: an endocrine society clinical practice guideline, *J. Clin. Endocrinol. Metab.* 100 (2015) 3975–4011.
- [57] S.A. Paschou, P. Anagnostis, D.G. Goulis, Weight loss for the prevention and treatment of type 2 diabetes, *Maturitas* 108 (2018) A1–2.
- [58] S.A. Paschou, A.D. Dede, P.G. Anagnostis, A. Vryonidou, D. Morganstein, D.G. Goulis, Type 2 diabetes and osteoporosis: a guide to optimal management, *J. Clin. Endocrinol. Metab.* 102 (2017) 3621–3634.
- [59] S.A. Paschou, P. Anagnostis, D.G. Goulis, I. Lambrinoudaki, Diet and lifestyle for post-reproductive health: focus on diabetes, *Case Rep. Women's Health* 18 (2018) e00056.
- [60] I. Lambrinoudaki, I. Ceasu, H. Depypere, T. Erel, M. Rees, K. Schenck-Gustafsson, T. Simoncini, F. Tremollieres, Y.T. van der Schouw, F.R. Pérez-López, EMAS position statement: diet and health in midlife and beyond, *Maturitas* 74 (2013) 99–104.
- [61] P. Anagnostis, S.A. Paschou, D.G. Goulis, V.G. Athyros, A. Karagiannis, Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit? *Maturitas* 108 (2018) 45–52.
- [62] A. Cano, P. Chedraui, D.G. Goulis, P. Lopes, G. Mishra, A. Mueck, L.M. Senturk, T. Simoncini, J.C. Stevenson, P. Stute, P. Tuomikoski, M. Rees, I. Lambrinoudaki, Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide, *Maturitas* 107 (2018) 7–12.
- [63] American Diabetes Association, Standards of medical care in diabetes, *Diabetes Care* 40 (Suppl. 1) (2017) S33–43.
- [64] S.A. Paschou, R.D. Leslie, Personalizing guidelines for diabetes management: twilight or dawn of the expert? *BMC Med.* 11 (2013) 161.
- [65] J. Upadhyay, S.A. Polyzos, N. Perakakis, et al., Pharmacotherapy of type 2 diabetes: an update, *Metabolism* 78 (2018) 13–42.